AndrewSKraftMD

Director of the University of Arizona Cancer Center Sydney E. Salmon Endowed Chair Associate Vice President for Oncology Programs for the University of Arizona Health Sciences Professor of Medicine in the Department of Medicine, Division of Hematology/Onc

Join to view full profile

Dr. Kraft is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kraft's full profile

Already have an account?

Office
1501 N Campbell Ave
Tucson, AZ 85724
Phone+1 520-694-0111

Fax+1 520-694-4085

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1983
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1975 - 1978
Perelman School of Medicine at the University of PennsylvaniaClass of 1975

Certifications & Licensure

CO State Medical License 1996 - 2025
AZ State Medical License 2014 - 2022
SC State Medical License 2004 - 2015
AL State Medical License 1983 - 1996
MD State Medical License 1978 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 1993

Clinical Trials

Bryostatin 1 in Treating Patients With Stage IV Breast Cancer Start of enrollment: 1998 Apr 01
Completed
Phase 2
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2004 Jun 08
Terminated
Phase 1
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer Start of enrollment: 2007 Jan 16
Completed
Phase 1
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer Start of enrollment: 2004 Oct 01
Terminated
Phase 2
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery Start of enrollment: 2005 Sep 21
Terminated
Phase 2
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 1
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2005 Mar 01
Completed
Phase 1
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery Start of enrollment: 2006 Jan 01
Completed
Phase 2
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Start of enrollment: 2011 Nov 03
Completed
Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

102 citations
Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase.
Stuart J. Frank, G Gilliland, Andrew S. Kraft, C S Arnold
Endocrinology. 1994-11-01
143 citations
PIM kinase (and Akt) biology and signaling in tumors.
Noel A. Warfel, Andrew S. Kraft
Pharmacology & Therapeutics. 2015-07-01
135 citations
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K. Schwartz, William D. Tap, Li-Xuan Qin, Michael B. Livingston, Samir D. Undevia
The Lancet. Oncology. 2013-04-01

Press Mentions

Shop TalkJuly 20th, 2019
Shop TalkDecember 10th, 2016
Dr. William Cance Hired to Lead University of Arizona Cancer Center in PhoenixNovember 6th, 2016

Grant Support

Senior LeadershipNational Cancer Institute2009–2012
Program Planning And EvaluationNational Cancer Institute2009–2012
Medical University Of South Carolina - Cancer Center Support GrantNational Cancer Institute2009–2012
Developmental FundsNational Cancer Institute2009–2012
Novel Inhibitors Of PIM Protein KinasesNational Cancer Institute2009
Mechanisms By Which Proteasome Enhance ApoptosisNational Cancer Institute2004–2007
Hollings Cancer Center Planning GrantNational Cancer Institute2003–2005
Mechanisms By Which Proteasome Enhance ApoptosisNational Cancer Institute2004
PIM 1 Protein Kinase As A Target For Drug DiscoveryNational Cancer Institute2003
PIM 1 Protein Kinase As A Target For Drug DiscoveryNational Cancer Institute2002–2003
Training In Pharmacology Of Antineoplastic AgentsNational Cancer Institute1999–2003
Control Of Differentiation Of Human PromyelocytesNational Cancer Institute1999–2003
Developmental Therapeutics ProgramsNational Cancer Institute2001–2002
Phase II Trial Of Bryostatin 1 For Treatment Of Stage IV Breast CancerNational Center For Research Resources1999–2002
Regulation Of Prostate Cancer Programmed Cell DeathNational Cancer Institute1998–2001
Phase I/II RX Of Chronic Myelogenous Leukemia With Bryostatin 1National Center For Research Resources1998–2000
Bryostatin 1 Treatment For Patients With Metastatic Malignant MelanomaNational Center For Research Resources1998–2000
Mechanism Of Action Of GM-CSFNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2000
Control Of Differentiation Of PromyelocytesNational Cancer Institute1996–1998
Bryostatin1 In Chronic Myelogenous LeukemiaNational Center For Research Resources1997
Bryostatin 1 In Metastatic Malignant MelanomaNational Center For Research Resources1996–1997
Differentiation Therapy Of Chronic Myelogenous LeukemiaNational Cancer Institute1996
Bryostatin 1 Therapy Of Metastatic MelanomaNational Cancer Institute1996
Differentiation Therapy Of Chronic Myelogenous LeukemiaNational Cancer Institute1995–1996
Control Of Differentiation Of PromyelocytesNational Cancer Institute1994–1996
Bryostatin 1 Therapy Of Metastatic MelanomaNational Cancer Institute1995
Mechanism Of Action Of GM-CSFNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1995
Control Of Differentiation Of Human PromyelocytesNational Cancer Institute1986–1993
The Role Of Protein Kinase C In Mediating N-RAS ProteinFogarty International Center1989